- Home
- AMRN vs SCPH Comparison
AMRN vs SCPH Comparison
Compare AMRN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- SCPH
- Stock Information
- Founded
- AMRN 1989
- SCPH 2013
- Country
- AMRN Ireland
- SCPH United States
- Employees
- AMRN N/A
- SCPH N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- SCPH Health Care
- Exchange
- AMRN Nasdaq
- SCPH Nasdaq
- Market Cap
- AMRN 216.0M
- SCPH 173.6M
- IPO Year
- AMRN 1993
- SCPH 2017
- Fundamental
- Price
- AMRN $17.13
- SCPH $4.06
- Analyst Decision
- AMRN Strong Sell
- SCPH Strong Buy
- Analyst Count
- AMRN 1
- SCPH 3
- Target Price
- AMRN $12.00
- SCPH $14.00
- AVG Volume (30 Days)
- AMRN 189.3K
- SCPH 251.2K
- Earning Date
- AMRN 07-30-2025
- SCPH 08-13-2025
- Dividend Yield
- AMRN N/A
- SCPH N/A
- EPS Growth
- AMRN N/A
- SCPH N/A
- EPS
- AMRN N/A
- SCPH N/A
- Revenue
- AMRN $214,112,000.00
- SCPH $41,982,000.00
- Revenue This Year
- AMRN N/A
- SCPH $108.95
- Revenue Next Year
- AMRN $7.88
- SCPH $73.83
- P/E Ratio
- AMRN N/A
- SCPH N/A
- Revenue Growth
- AMRN N/A
- SCPH 138.10
- 52 Week Low
- AMRN $7.08
- SCPH $1.94
- 52 Week High
- AMRN $17.30
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- AMRN 75.75
- SCPH 59.89
- Support Level
- AMRN $16.12
- SCPH $3.83
- Resistance Level
- AMRN $17.30
- SCPH $4.14
- Average True Range (ATR)
- AMRN 0.96
- SCPH 0.16
- MACD
- AMRN 0.11
- SCPH -0.03
- Stochastic Oscillator
- AMRN 96.60
- SCPH 81.40
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.